Genzyme Expands
ePT--the Electronic Newsletter of Pharmaceutical Technology
Cambridge, MA (June 7)-Genzyme Corp. is growing, with a new biomanufacturing plant planned and other expansions nearing completion.
Cambridge, MA (June 7)-Genzyme Corp. is growing, with a new biomanufacturing plant planned and other expansions nearing completion.
The company is investing EUR105 million (nearly $140 million) in a new 140,000-ft2 biomanufacturing plant in Lyon, France to replace its smaller plant in nearby Marcy l’Etoile. The new plant, which will be used to manufacture Genzyme’s transplantation treatment “Thymoglobulin,” will have more than twice the manufacturing capacity of the Marcy facility and will create as many as 50 new jobs. The facility’s nine-acre site leaves room for expansion should demand for Thymoglobulin continue to rise.
Genzye also is completing development of a new plant in Belgium, which will be used to produce monoclonal antibodies and proteins. The company intends to expand other facilities, including its Allston Landing protein manufacturing plant in Boston. In addition, a new filling and packaging facility at Genzyme’s manufacturing site in Ireland recently received regulatory approvals.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
